Q2 EPS Forecast for C4 Therapeutics Boosted by Analyst

C4 Therapeutics, Inc. (NASDAQ:CCCC) – Brookline Capital Markets raised their Q2 2026 earnings per share (EPS) estimates for C4 Therapeutics in a research note issued on Tuesday, May 12th. Brookline Capital Markets analyst L. Cann now expects that the company will earn ($0.20) per share for the quarter, up from their previous estimate of ($0.21). The consensus estimate for C4 Therapeutics’ current full-year earnings is ($1.01) per share. Brookline Capital Markets also issued estimates for C4 Therapeutics’ Q3 2026 earnings at ($0.21) EPS, Q4 2026 earnings at ($0.22) EPS, FY2026 earnings at ($0.83) EPS, FY2027 earnings at ($0.98) EPS, FY2028 earnings at ($1.71) EPS, FY2029 earnings at $6.14 EPS and FY2030 earnings at $23.44 EPS.

C4 Therapeutics (NASDAQ:CCCC) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.20) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.05. The business had revenue of $6.15 million for the quarter, compared to analysts’ expectations of $4.42 million. C4 Therapeutics had a negative net margin of 297.76% and a negative return on equity of 50.68%.

CCCC has been the subject of a number of other reports. Barclays upped their price target on shares of C4 Therapeutics from $5.00 to $7.00 and gave the stock an “overweight” rating in a research note on Thursday, February 26th. Weiss Ratings reissued a “sell (d-)” rating on shares of C4 Therapeutics in a report on Monday, April 20th. TD Cowen restated a “buy” rating on shares of C4 Therapeutics in a research report on Thursday, February 26th. increased their price target on C4 Therapeutics from $20.00 to $30.00 and gave the company a “buy” rating in a research note on Monday, February 23rd. Finally, Wall Street Zen upgraded C4 Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Saturday, February 28th. Five equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $7.75.

C4 Therapeutics Stock Down 1.4%

Shares of CCCC opened at $3.63 on Friday. The firm has a market capitalization of $399.96 million, a PE ratio of -3.05 and a beta of 2.77. The firm has a 50-day moving average price of $2.87 and a 200 day moving average price of $2.48. C4 Therapeutics has a 52-week low of $1.21 and a 52-week high of $3.95.

Hedge Funds Weigh In On C4 Therapeutics

Several hedge funds have recently made changes to their positions in the business. Zacks Investment Management bought a new stake in C4 Therapeutics during the third quarter worth approximately $29,000. Delta Investment Management LLC acquired a new position in shares of C4 Therapeutics in the 4th quarter worth $38,000. Virtu Financial LLC acquired a new position in shares of C4 Therapeutics in the 4th quarter worth $39,000. Acadian Asset Management LLC acquired a new stake in shares of C4 Therapeutics during the first quarter worth $43,000. Finally, Caitong International Asset Management Co. Ltd purchased a new stake in shares of C4 Therapeutics during the third quarter valued at $43,000. Institutional investors and hedge funds own 78.81% of the company’s stock.

About C4 Therapeutics

C4 Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted protein degraders. Utilizing its proprietary Controlled Inducible Degradation (CiD) platform, the company seeks to eliminate disease-causing proteins by harnessing the body’s natural protein disposal machinery. This approach aims to address a wide range of oncology and immuno-oncology indications by targeting proteins that have historically been difficult to inhibit with traditional small molecules or antibodies.

The company’s pipeline includes multiple small-molecule degrader candidates advancing through preclinical and clinical stages.